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Abstract: It is estimated that not less than USD 28 billion are spent each year in the USA alone on
irreproducible pre-clinical research, which is not only a fundamental loss of investment and resources
but also a strong inhibitor of efficiency for upstream processes regarding the translation towards clin-
ical applications and therapies. The issues and cost of irreproducibility has mainly been published on
pre-clinical research. In contrast to pre-clinical research, test material is often being transferred into
humans in clinical research. To protect treated human subjects and guarantee a defined quality standard
in the field of clinical research, the manufacturing and processing infrastructures have to strictly follow
and adhere to certain (inter-)national quality standards. It is assumed and suggested by the authors
that by an implementation of certain quality standards within the area of pre-clinical research, billions
of USD might be saved and the translation phase of promising pre-clinical results towards clinical appli-
cations may substantially be improved. In this review, we discuss how an implementation of a quality
assurance (QA) management system might positively improve sample quality and sustainability within
pre-clinically focused biobank infrastructures. Biobanks are frequently positioned at the very beginning
of the biomedical research value chain, and, since almost every research material has been stored in a
biobank during the investigated life cycle, biobanking seems to be of substantial importance from this
perspective. The role model of a QA-regulated biobank structure can be found in biobanks within the
context of clinical research organizations such as in regenerative medicine clusters.
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rogenic cells into the neuromuscular network is a prerequisite for 
satisfactory results. Given these conditions, appropriate in vivo 
animal models will be necessary to assess safety and efficacy of 
neuroregenerative approaches.
The second paper by Smolar et al. [12] deals with impaired 
bladder function and the potential for corrective intervention by 
TERM. Since more than two decades, scientists and surgeons have 
tried to use tissue engineering to replace or complete surgical treat-
ments which often have disappointing outcome. Smolar et al. give 
a comprehensive overview on the hypes and hopes of the field. 
However, not only the complex anatomy of the hollow organ cre-
ates a challenge to bladder tissue engineering but also its proper 
innervation and vascularization of the tissue which is a prerequisite 
for satisfactory functional results. Urine-derived stem cells, mesen-
chymal and adipose tissue-derived stem cells in combination with 
various artificial biomaterials and growth factors are the tools for 
bladder tissue engineering. Unfortunately, despite sophisticated 
applications of TERM technologies, the generation of properly 
working bladder tissue is still awaited.
Ruangsawasdi et al. [13] give an intriguing insight into the 
physiology of site-specific tissue regeneration, presenting experi-
mental work of regenerative endodontology. Infected or necrotic 
immature teeth often degenerate upon standard treatment. Tissue 
engineering approaches offer an attractive alternative to conven-
tional treatment options. In a rat model, the authors show convinc-
ing data for site-specific pulp-like tissue formation by transplanta-
tion of tooth specimens at the calvaria area as opposed to the im-
plantation into the dorsal subcutis. The findings by Ruangsawasdi 
et al. remind on the observation by Lee et al. [14] showing scarless 
tendon defect repair by transplantation of in vitro expanded ten-
don-derived stem/progenitor cells. Obviously, even bradythrophic 
tissue contains enough residing stem cells with sufficient capacity 
for tissue-specific regeneration provided the microenvironment is 
permissive for respective cell proliferation and differentiation.
Tissue engineering (TE) combines the three components – cells, 
scaffolds and growth factors – to generate tissues for functional re-
placement of damaged or diseased organs upon transplantation. 
Further, regenerative medicine (RM) combines TE with other 
strategies such as cell-based therapies, gene therapy, and immu-
nomodulation, using stem and progenitor cells from various 
sources in order to induce in vivo organ regeneration [1–3]. 
TERM, the combination of TE and RM, combines basic sciences 
such as nanotechnology, biomechanics, bioinformatics, material 
science, and polymer chemistry with cell biology and medical sci-
ences to promote functional organo(re)genesis. In the light of a 
growing and aging population with ever increasing demand of 
organ replacements, TERM might become the appropriate strategy 
to meet future needs of the patients [4].
Part 1 of the current special topic which was published in the 
preceding issue of Transfusion Medicine and Immunotherapy 
(issue 4, 2016) summarized the use of various stem cell populations 
such as mesenchymal as well as hematopoiesis- and adipose tissue-
derived stem cells in the context of tissue regeneration, immune 
modulation and as transplantation additives [5–7]. In addition, 
several contributions provided comprehensive reviews on myocar-
dial, cardiovascular and cardiovalvular tissue regeneration [8–10]. 
The current part 2 of this special topic puts the focus on genera-
tion of organ-specific tissues in order to functionally replace dam-
aged organs. Also, regulatory aspects as well as quality issues for 
clinical application of tissue engineering will be addressed. 
The first article by Jessberger et al. [11] summarizes current in-
sights into regenerative capacity of adult brain tissue. Although 
loss of brain tissue is still associated with functional deficits, the 
discovery of neurogenic stem cells, their transcription factors and 
regulators, and of neurogenic niches in the adult brain opens a new 
view on regenerative potential of the adult brain. However, not 
only neurogenic differentiation of cells is required for functional 
brain regeneration, but also the correct integration of induced neu-
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The review by Bhattacharya et al. [15] from the same group fo-
cuses on bone tissue regeneration. Bone tissue has a high regenera-
tive capacity for scarless healing of fractures. However, dehiscent 
bone defects after trauma or tumor resection resist healing and 
leave behind large bone defects ultimately requiring mutilating 
surgery. The successful use of bone autografts and cell-free allo-
grafts to rescue continuity and induction of new bone formation 
reflects the extensive regenerative capacity of bone tissue. Bone 
transplant shortage, transplant infection, and technical restrictions 
in autologous transplant sample preparation triggered the evalua-
tion of tissue engineering options for bone regeneration. Bhat-
tacharya et al. review the three components which are needed for 
successful ex vivo bone engineering: scaffolds, cells, and growth 
factors. Critical aspects of cell-based engineered bone implants 
such as vascularization, tissue hypoxia, scaffold production, and 
growth factor combinations as well as clinical hurdles in use of ar-
tificial bone implants are addressed.
The concluding two articles focus on regulatory and organiza-
tional issues of TERM in order to assure reliant, robust, and repro-
ducible health care services. Hartmannn-Fritsch et al. [16] summa-
rize the relevant conditions, definitions, and practical issues to be 
considered in fabrication of advanced therapy medicinal products 
(ATMPs). Their extensive experience in provision of artificial skin 
replacements allows them to summarize comprehensively the pro-
cess necessary for clinical grade products and services. In addition 
regulatory hurdles and commercial conditions for marketing of 
ATMPs are discussed.
Simeon-Dubach et al. [17] give a view on translating pre-clinical 
science into clinical applications. According to the authors, about 
USD 28 billion are spent each year in the USA for non-reproduci-
ble research which represents a huge loss of investment and inhib-
its translation of research towards clinical therapies. They empha-
size on the importance to adhere proper quality assurance stan-
dards as well as the so-called Biospecimen Reporting for Improved 
Study Quality (BRISQ) and various quality assurance programs for 
biobanking such as the Canadian Tissue Repository Network 
(CTRNet) or College of American Pathologist (CAP) accreditation 
program. The resources are referenced and may be consulted di-
rectly by the interested reader. The authors refer to the National 
Institutes of Health-proposed roadmap for translation of basic sci-
ence discoveries into clinical practice and indicate that additional 
community and public health research may be important for suc-
cessful translation.
The huge field of TERM can only be tipped on by these two 
parts of special issue of TMH. Many relevant fields such as scaffold 
production, bioreactor technology, cell expansion and reprogram-
ming as well as many promising clinical applications of TERM are 
left behind due to space restriction. However, there are numerous 
excellent reviews available for each of these topics which the reader 
is referred to [18–23]. Also, the site of clinical trials (https://clinical-
trials.gov) is a comprehensive repository for ongoing clinical re-
search in tissue engineering and regenerative medicine.
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